# Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

> **NCT01774578** · PHASE2,PHASE3 · TERMINATED · sponsor: **NewLink Genetics Corporation** · enrollment: 135 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Progression of Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Recurrent

## Interventions

- **DRUG:** Docetaxel
- **BIOLOGICAL:** HyperAcute®-Lung Immunotherapy
- **DRUG:** Gemcitabine
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT01774578
- **Lead sponsor:** NewLink Genetics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-02
- **Primary completion:** 2016-05-18
- **Final completion:** 2016-06-18
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01774578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01774578, "Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01774578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*